[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Manchester\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":634},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,55,83,102,130,152,183,209,234,253,278,316,336,357,382,402,424,445,466,484,514,539,558,584,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100602228","positron-emission-tomography-to-assess-the-effect-of-camzyos-on-ischaemia-in-hocm-peach-trial-100602228",false,"NCT07120776","Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial","Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in Hypertrophic Obstructive Cardiomyopathy: The PEACH Trial","PEACH","Inclusion Criteria:\n\n1. Written informed consent.\n2. Aged 18 and over.\n3. Confirmed diagnosis of Hypertrophic Obstructive Cardiomyopathy (HOCM) based on diagnostic criteria, such as unexplained left ventricular hypertrophy with a maximal wall thickness ≥15 mm in the absence of uncontrolled hypertension, valvular heart disease, or HCM phenocopies such as amyloidosis and storage disorders, and presence of either a resting or provoked peak left ventricular outflow tract (LVOT) gradient ≥30 mmHg.\n4. Symptoms suggestive of myocardial ischaemia (chest pain, shortness of breath on exertion) with a clinical indication for Rb-PET.\n5. Eligible for Mavacamten treatment according to standard clinical guidelines. \\[see: https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002Fta913\u002Fchapter\u002F1-Recommendations\\]. Mavacamten is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way.\n6. PET-CT performed for clinical reasons at any time in the preceding 18 months if reported as abnormal.\n\nExclusion Criteria:\n\n1. Patients with obstructive coronary artery disease (epicardial coronary stenosis \\>50%, assessed by either invasive coronary angiography or computed tomography angiography (CTCA). Patients will undergo the initial PET study as part of their routine clinical care. If evidence of ischaemia is identified, the standard next step would involve either CT coronary angiography or, in some cases, invasive angiography to guide further clinical management. If the angiography reveals a clear lesion responsible for the ischaemia identified on PET, the patient will not be eligible for inclusion in the study and will not be approached. Conversely, if the angiography does not identify a definitive cause for the ischaemia, it will be presumed to be of microvascular origin. In such cases, the patient becomes eligible for the study and will be approached to discuss participation and provide consent at this stage. It is important to emphasize that any angiographic procedure occurs prior to consent and as part of routine clinical care. No angiographic investigations are planned or conducted as part of the study protocol. Data from the clinical angiogram will not be included in the study, except to note a 'positive angiogram' as a reason for patient exclusion.\n2. Contraindications to Mavacamten, including left ventricular ejection fraction (LVEF) less than 55%, hypersensitivity or allergic reaction to the drug.\n3. Contraindication to Rubidium PET-CT, including:\n\n   * Pregnancy or breastfeeding.\n   * Severe claustrophobia.\n   * Morbid obesity when the patient dimensions are beyond the scanning chamber capacity.\n4. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his\u002Fher participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.","ALL","18 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart muscle in the absence of blockages in the coronary arteries.\n\nDespite proven advances in treatment of LVOT obstruction with the novel medication Camzyos (Mavacamten), there is a limited understanding of its effect on myocardial ischaemia.\n\nThis study, called the PEACH Trial, is designed to assess whether Camzyos also improves blood supply (perfusion) to the heart muscle in patients with HOCM. A specialised imaging technique called Positron Emission Tomography\u002FComputed Tomography (PET-CT), using Rubidium-82 will be used to evaluate blood flow to the heart muscle before and after treatment. Camzyos is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way.\n\nParticipants with HOCM who are starting treatment with Camzyos as part of their clinical care will undergo a baseline PET-CT scan (if not already done), and a second scan after 12 months. The follow-up scan is done solely for research purposes. The scans will allow researchers to evaluate whether the medication improves myocardial perfusion in addition to relieving outflow obstruction.\n\nThe study is sponsored by the University of Manchester and funded by Bristol Myers Squibb. It will involve up to 75 participants recruited at Manchester University NHS Foundation Trust. The findings could help improve understanding of how Camzyos works and support personalised treatment approaches in HOCM.",[28,29,30],"Hypertrophic Obstructive Cardiomyopathy \\(HOCM\\)","Left Ventricular Outflow Tract Obstruction","Myocardial Ischaemia",[32,33,34,35,36,37,38,39,40,41],"Camzyos","Mavacamten","HOCM","HCM","Cardiac PET","Rubidium-82 PET-CT","Myocardial Perfusion","Nuclear cardiology","Left ventricular outflow obstruction","Cardiomyopathy","RECRUITING","2026-05-19",{"date":45,"type":46},"2026-05-22","ACTUAL",{"date":48,"type":46},"2026-03-26",{"date":50,"type":22},"2028-10",{"name":52,"class":53},"University of Manchester","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":54},"100576573","selecting-hypoxic-tumours-for-treatment-modification-100576573","NCT06787053","Selecting Hypoxic Tumours for Treatment Modification","SELECT","Inclusion Criteria:\n\nThis will be tumour site dependent.\n\nBladder:\n\n* Older than age 18 years.\n* Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.\n* Able to give informed consent.\n\nCervix:\n\n* Older than age 18 years.\n* Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.\n* Able to give informed consent.\n\nProstate:\n\n* Older than age 18 years.\n* Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner.\n* Able to give informed consent.\n\nExclusion Criteria:\n\nThis will be tumour site dependent\n\nBladder:\n\n* Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.\n* Unable to tolerate MRI scans.\n* Pregnancy.\n\nCervix:\n\n* Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.\n* Unable to tolerate MRI scans.\n* Pregnancy.\n\nProstate:\n\n* Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.\n* Unable to tolerate MRI scans",{"count":63,"type":22},30,"OBSERVATIONAL","Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (\\>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxic tumours have a poor prognosis. This can be improved with treatment intensification. Treatment intensification can be modification with CON (breathing O2-enriched air + oral administration of nicotinamide), chemoradiosensitisation, radiation dose-escalation or additional systemic treatments, significantly improving response of the tumours to radiotherapy. However, there are currently no clinically approved biomarkers to identify hypoxic tumours. Our group has developed and validated gene-expression signature-based biomarkers that identify patients with hypoxic bladder, head and neck , prostate, sarcoma and lung cancers. The bladder cancer gene-expression hypoxia signature has been shown to predict benefit from hypoxia modification using RNA from archived tumour tissue. The main purpose of this study is to demonstrate in at least two cancer types that the hypoxia biomarker predicts benefit from hypoxia modification in real-time.",[67,68],"Bladder (Urothelial, Transitional Cell) Cancer","Prostate Cancer",[70,71,72,73,74],"Hypoxia","Bladder","Cervix","Prostate","Hypoxia Modification","2026-05-09",{"date":77,"type":46},"2026-05-12",{"date":79,"type":46},"2024-10-16",{"date":81,"type":22},"2028-05-30",{"name":52,"class":53},{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":54},"100431832","mr-bio-a-study-to-evaluate-changes-in-mr-imaging-and-biological-parameters-100431832","NCT04903236","MR-BIO: A Study to Evaluate Changes in MR Imaging and Biological Parameters","MR-BIO","Inclusion Criteria:\n\nBe willing and able to provide written consent. Over 18 years of age. Undergo and satisfy MRI Safety Screening Patient volunteers must be under the care of a clinical oncologist at The Christie NHS Foundation Trust and be planned to receive radiotherapy to the target site to be imaged.\n\nPatient volunteers must be able to give blood and\u002For urine sample as required through the treatment period.\n\nNon-patient (healthy) volunteers must have no known or suspected significant medical condition.\n\nExclusion Criteria:\n\nThe following apply to both patients and healthy volunteers:\n\nAny conditions that would be a contra-indication to MRI including:\n\n* Failure to satisfy MRI Safety Screening Form\n* Implanted pacemakers and\u002For pacing wires\n* Cochlear implants\n* Programmable hydrocephalus shunts\n* Ferromagnetic implants\n* Unable to tolerate MR scans\n* Known HIV or active HepB or C\n* Pregnancy Healthy volunteers must not be a member of the study team.",true,{"count":92,"type":22},250,"The MR BIO study aims to understand the changes in the tumour and normal tissues during a course of radiotherapy. This is accomplished by studying the MR images taken during each treatment session on the MR Linear accelerator (MR Linac). The overarching hypothesis is that changes in MR imaging and biological parameters from blood, tissue, or urine biomarkers can be measured during radiotherapy and associated with clinical outcome.\n\nThe MR Linac is a new radiotherapy machine with an on board MR scanner. This enables us to take images with high resolution and target the tumours more precisely and also reduce the dose to normal tissues. All patients undergoing treatment in the MR Linac at the Christie hospital will be considered for enrolment regardless of tumour site being treated.\n\nThe study participants will receive the standard of care treatment for their disease condition. In addition, they will be requested to give weekly blood and urine samples during the course of radiotherapy and at first follow up. On completion of radiotherapy treatment, the participants will continue to be on standard of care follow up protocol with the treating oncologist.\n\nA small cohort of ten healthy volunteers will also be recruited to the study to develop and select some of the MR sequences only; they will not provide blood or urine samples. The healthy volunteers will be scanned for no more than one hour per session for a maximum of two sessions in total. These optimised sequences can then be used in the patient cohort.",[95],"Cancer",{"date":77,"type":46},{"date":98,"type":46},"2020-10-20",{"date":100,"type":22},"2026-12-31",{"name":52,"class":53},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100586938","the-biomechanical-outcomes-of-autologous-chondrocyte-implantation-100586938","NCT06921889","The Biomechanical Outcomes of Autologous Chondrocyte Implantation","Investigating the Biomechanical and Functional Outcomes of Autologous Chondrocyte Implantation: A Multi-centre Study","Inclusion Criteria:\n\n* Diagnosis of a chondral injury to the knee by a consultant orthopaedic surgeon Participants must have this diagnosis, else they are not eligible for ACI surgery.\n* Listed for ACI for a chondral injury by a consultant orthopaedic surgeon Participants must be listed for ACI, as this is the treatment of interest in this research study\n* Over 18 years old Participants must be legally capable of providing informed consent for the study.\n\nExclusion Criteria:\n\n* Listed for any treatment other than ACI Participants must be listed for ACI, as this is the treatment of interest in this research study\n* Under 18 years old. Participants must be legally capable of providing informed consent for the study.",{"count":110,"type":22},47,"Injury to the knee can damage the lining of the knee's bones, called cartilage. Cartilage injuries cause pain and limit movement, making activities like walking, playing sports, and working difficult.\n\nCartilage cannot repair itself well, so surgery is often needed to repair it. People who have cartilage repair surgery want to return to normal activities after their operation. Doctors and scientists know the operation can reduce pain, but do not fully understand how it affects movement.\n\nThis research will help us see if knee function gets better after cartilage repair surgery. The results will help doctors and patients understand what to expect from the surgery. It could also uncover common problems after surgery that could be fixed with physiotherapy.\n\nThis research is important because untreated cartilage injuries can develop into arthritis later in life. Arthritis is a painful lifelong condition that could be prevented by effectively treating the cartilage injury.\n\nIn this study, adult patients who are waiting to have a type of cartilage repair surgery called 'autologous chondrocyte implantation' (ACI) at one of 7 hospitals will be invited to take part in the study by their surgeon. Patients who decide to take part will be invited to two appointments at their own hospital, where assessments of their knee function will be performed. The tests will assess the knee's movement, and the patient's balance and walking abilities. The first research appointment will take place before the operation, and the second and final appointment will take place 6-months after surgery. The results of this study will help us understand how knee function changes after cartilage repair surgery.\n\nThe study will take place across 7 ACI centres in England, and is funded by Orthopaedic Research UK and the British Association for Surgery of the Knee.",[113],"Chondral Defect",[115,116,117,118,119,120],"Chondral defect","Cartilage repair","Knee","Autologous chondrocyte implantation","Biomechanical outcome","Gait","2026-05-01",{"date":123,"type":46},"2026-05-07",{"date":125,"type":46},"2024-04-22",{"date":127,"type":22},"2026-07-13",{"name":52,"class":53},7,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":136,"enrollmentInfo":137,"targetDuration":139,"studyType":64,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":54},"100622305","multicentre-hypertrophic-cardiomyopathy-registry-100622305","NCT07381894","Multicentre Hypertrophic Cardiomyopathy Registry","Inclusion Criteria:\n\n* Confirmed diagnosis of Hypertrophic Cardiomyopathy (HCM) clinically and not solely explained by abnormal loading conditions (e.g., significant hypertension, valvular disease\n\nExclusion Criteria:\n\n* Participants who do not fulfil the imaging and clinical diagnostic criteria of HCM","99 Years",{"count":138,"type":22},2500,"5 Years","Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow tract obstruction), shortness of breath, and an increased risk of heart failure or sudden cardiac arrest.\n\nWhile standard treatments exist and new targeted medications (cardiac myosin inhibitors) have recently been approved, doctors still need better data to predict which treatments will work best for each individual patient. This national registry based in the UK is a secure database that collects health information from HCM patients across multiple NHS hospital sites in the UK over several years.\n\nParticipants in this study will have their routine health information collected from their medical records, including details from heart scans (echocardiograms and MRIs), blood tests, and genetic information. With this HCM registry, we aim to improve disease understanding and risk prediction, paving the way for more personalised treatment plans for the HCM community in the future",[142],"Hypertrophic Cardiomyopathy (HCM)",[144],"hypertrophic cardiomyopathy","2026-04-27",{"date":121,"type":46},{"date":148,"type":46},"2026-04-01",{"date":150,"type":22},"2029-01-01",{"name":52,"class":53},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":90,"sex":159,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":164,"conditions":165,"keywords":172,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100606285","st-marys-assisted-reproductive-technology-and-cardiometabolic-health-modifiable-targets-for-multimorbidity-prevention-start-healthy-100606285","NCT07173569","St Mary's Assisted Reproductive Technology and Cardiometabolic Health: Modifiable Targets for Multimorbidity Prevention (START-HEALThY)","START-HEALThY","Inclusion Criteria:\n\n* In pre-conception cohort:\n\n  * Aged between 16 and 45\n  * Able to provide informed consent\n  * Either: 1) Those with a history of infertility (failure to conceive after at least 1 year of unprotected intercourse\u002F3-6 cycles of Intra-Uterine Insemination (IUI) or diagnosed cause of infertility) and accepted for IVF at The Department of Reproductive Medicine, MFT or, 2) attending for a pre-conception appointment at MFT\n  * Nulliparous (no previous pregnancies beyond 20 weeks)\n  * No pre-existing heart disease, hypertensive disease, vascular disease or diabetes\n* In post-pregnancy cohort\n\n  * Aged between 16 and 45\n  * Able to provide informed consent\n  * Participant of START clinic study (achieved pregnancy via a) IVF with or without ICSI treatment, b) spontaneous conception without medical intervention within 12 months, or c) spontaneous conception following ovulation induction for delay in spontaneous conception \\>12 months or confirmed anovulation)\n\nExclusion Criteria:\n\n\\- In all participants:\n\n* Prisoners\n* Born male at birth\n* Language barrier not overcome by telephone or video interpretation services\n* Pregnant at time of study visit\n\nPre-conception participants only:\n\n• Accepted for IVF for non-infertility reasons i.e. egg donation, egg collection, egg banking, gestational surrogacy","FEMALE","16 Years","45 Years",{"count":163,"type":22},120,"The main causes of death in women are conditions affecting the heart and blood vessels (cardiovascular disease, CVD). Women who have difficulties getting pregnant (infertility) may be at increased risk, but the reasons for this are not clear. Infertility itself may be linked with poorer heart and blood vessel health, or fertility treatments such as in vitro fertilisation (IVF) could increase the risk.\n\nThe study aims to understand the practicalities of obtaining detailed profiling of women's pre- and post- pregnancy heart, blood vessel and metabolic health. Two groups of women in Manchester University NHS Foundation Trust, will be recruited over 2 years: 1) women planning a pregnancy, either spontaneously or with IVF treatment after infertility, 2) women who previously took part in a pregnancy health study after IVF or non-IVF conception.\n\nParticipants will attend a single research appointment where they will undergo a cardiometabolic health assessment. They will have their BMI calculated, body composition measured, a measurement of how well their blood vessels work using a blood pressure cuff around the arm and\u002For finger and blood sampling performed. A blood pressure cuff as well as a blood sugar sensor may be fitted to be worn after the appointment. Participants will be asked to complete a questionnaire(s), with follow-up for up to 13 months.\n\nThe cardiometabolic health of those who conceived with or without IVF treatment and with or without a history of infertility will be compared at both time points to investigate the possibility of links between infertility, IVF processes and CVD risk and to understand any potential barriers to recruitment of individuals at either time point to guide future studies. This information could then be used in a full-scale study, including in pregnancy, to improve care and promote lifelong health for women with infertility.",[166,167,168,169,170,171],"Maternal Cardiometabolic Health","Infertility","Assisted Reproductive Technology","Cardiovascular Health","Metabolic Health","in Vitro Fertilisation",[173,174,175],"Feasibility study","Ambulatory cardiometabolic health monitoring","Cohort","NOT_YET_RECRUITING",{"date":178,"type":46},"2026-04-28",{"date":121,"type":22},{"date":181,"type":22},"2028-10-31",{"name":52,"class":53},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":90,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":208,"locationsCount":4},"100631854","using-if-then-plans-to-support-healthcare-professionals-in-raising-patient-safety-concerns-100631854","NCT07506096","Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns","Using IF-THEN Plans to Support Healthcare Professionals in Raising and Responding to Patient Safety Concerns.","Inclusion Criteria:\n\nAged 18 years and over\n\n* Currently working as a healthcare professional in a health or social care setting\n* Good understanding of written and spoken English\n\nExclusion Criteria:\n\n* Aged under 18 years\n* Not currently working as a healthcare professional in a health or social care setting\n* Poor understanding of written and spoken English",{"count":191,"type":22},1000,[25],"This study aims to test whether a brief behavioural intervention can help healthcare professionals raise and respond to patient safety concerns in their work. Healthcare professionals are often encouraged to speak up about safety risks, but barriers such as time pressure, uncertainty, and workplace culture can make this difficult.\n\nParticipants will complete an online questionnaire about their experiences of patient safety risks and how often they raise concerns. They will then be randomly assigned to one of two groups. One group will complete a short planning exercise (\"if-then\" plans) designed to help them act when they notice safety concerns, while the other group will not receive this exercise. Participants will be invited to complete follow-up questionnaires at approximately one month and six months to assess how often they have raised or responded to safety concerns since taking part.",[195],"Patient Safety Concerns",[197,198,199,200,201],"patient safety","implementation intentions","behaviour change","safety concerns","randomised controlled trial","2026-04-20",{"date":204,"type":46},"2026-04-23",{"date":206,"type":22},"2026-05-31",{"date":100,"type":22},{"name":52,"class":53},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":90,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100630983","a-feasibility-randomised-control-trial-to-evaluate-early-perinatal-bereavement-counselling-for-parents-who-have-experienced-a-perinatal-death-100630983","NCT07494760","A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experienced a Perinatal Death","Perinatal Loss - Early Referral for Counselling (PEARL-C): A Feasibility Randomised Controlled Trial","PEARL-C","Inclusion Criteria:\n\n* Women and partners of women who have had a late fetal loss (from 16 weeks), stillbirth or neonatal death within the maternity unit at Wythenshawe Hospital.\n* For the qualitative interviews, healthcare professionals who have been involved with referrals to the intervention and\u002For the delivery of the intervention\n\nExclusion Criteria:\n\n* Less than 16 years of age\n* Anyone who lacks the capacity to consent\n* Inability to read English (interpreters will be provided for counselling sessions and interviews if needed).",{"count":218,"type":22},26,[25],"The goal of this feasibility randomised control trial is to determine if a trial to evaluate perinatal bereavement counselling for parents who have experienced a perinatal death is feasible. The main question it aims to answer is:\n\n• Is a trial to evaluate access to perinatal bereavement counselling feasible?\n\nResearchers will compare the intervention group (parents who have received counselling) to the control group (parents who have not received counselling) to see if there are differences in measurements of parents' grief and psychological symptoms.\n\n* Participants allocated to the intervention and control group will receive usual bereavement care from the perinatal bereavement team at the hospital\n* Parents allocated to the intervention group will receive counselling\n* Parents will complete validated psychometric questionnaires about their levels of perinatal grief, psychological distress, depression, and quality of life\n* Parents in the intervention group will be asked a series of open-ended written questions about their experience of participating in the trial\n* Healthcare professionals who have been involved with delivery of the intervention\u002Freferrals will be interviewed about their experience of the trial.",[222,223,224,225],"Stillbirth","Perinatal Death","Psychological","Grief","2026-03-20",{"date":228,"type":46},"2026-03-27",{"date":230,"type":22},"2026-03-01",{"date":232,"type":22},"2027-09-01",{"name":52,"class":53},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":90,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":252,"locationsCount":4},"100599407","using-if-then-plans-to-support-patients-in-raising-safety-concerns-about-their-care-100599407","NCT07084090","Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care","Inclusion Criteria:\n\nAged 18 and over Good verbal and written understanding of English\n\nExclusion Criteria:\n\nAged under 18 years of age Poor verbal and written understanding of English",{"count":241,"type":22},10000,[25],"The aim of the present research is to test the effectiveness of an implementation intention-based intervention for promoting the raising of safety concerns by patients in healthcare settings.\n\nEach participant will be randomly allocated to one of two conditions: (1) a control condition, and (2) an intervention condition, in which participants form multiple implementation intentions (i.e. \"if-then\" plans) using a structured online interface. The main outcome measure will be the frequency with which participants report raising safety concerns in healthcare settings over a 12-month follow-up period.",[195],[246,198,199,200,201],"Patient safety","2026-03-18",{"date":249,"type":46},"2026-03-19",{"date":226,"type":22},{"date":100,"type":22},{"name":52,"class":53},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":159,"minAge":160,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":54},"100392687","the-tommys-national-rainbow-clinic-study-100392687","NCT04393259","The Tommy's National Rainbow Clinic Study","The Tommy's National Rainbow Clinic Study: Evaluation of a Specialist Antenatal Service for Women and Families Following a Stillbirth or Neonatal Death","Inclusion Criteria:\n\n* Women who are attending the Rainbow Clinic because they have had prior stillbirth, neonatal death or late termination of pregnancy\n* Women who are currently pregnant\n\nExclusion Criteria:\n\n* Less than 16 years of age\n* Anyone who lacks capacity to consent","50 Years",{"count":262,"type":22},500,"The death of a baby before or shortly after birth affects approximately 1 in every 250 pregnancies in the UK meaning that over 4,000 parents experience the death of a baby each year in the UK. The majority of women who have experienced the loss of a baby will have another pregnancy, usually within a year.\n\nOur analysis of 14 studies concluded that parents need specialist support from doctors and midwives in a future pregnancy to reduce the risk of pregnancy complications and to provide the care and support they need. The Rainbow Clinic model aims to provide specialist care and support to families who have experienced the death of a baby during pregnancy or shortly afterwards. Rainbow Clinic was initially established in St Mary's Hospital, Manchester in 2013.\n\nThe Rainbow Clinic team are now working to establish Rainbow Clinics in other maternity units throughout the UK. As this is a new clinical service the investigators would like to evaluate the care provided in the Rainbow clinics across the United Kingdom, to look at women's experiences of care, their levels of anxiety and depression, to identify where care can be improved and the pregnancy outcomes of women attending Rainbow Clinic. This evaluation needs information about pregnancy outcomes and women's experiences. Participation in this research study will allow us to collect and aggregate this information. The investigators will ask all women attending participating Rainbow Clinics to complete a short questionnaire early in their pregnancy and again at the end. The study will collect information about the outcome of their pregnancy.",[222],[266,267,268,269],"Pregnancy after loss","Antenatal care","Anxiety","Depression","2026-03-12",{"date":272,"type":46},"2026-03-16",{"date":274,"type":46},"2020-12-01",{"date":276,"type":22},"2027-09-30",{"name":52,"class":53},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":18,"minAge":160,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":292,"conditions":293,"keywords":299,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},"100621612","phase-1-granulocyte-augmented-cord-blood-transplantation-for-poor-risk-leukaemia-100621612","NCT07372885","GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia","A Multi-centre Phase I\u002FII Trial of Granulocyte-augmented Cord Blood Transplantation for Young Adults With Very Poor Risk Acute Myeloid Leukaemia.","GRACE","INCLUSION CRITERIA:\n\n1. Availability of a suitable cord blood unit\n2. Age between 16 and 55 years\n3. Primary diagnosis of Acute Myeloid Leukaemia (AML) or MDS\u002FAML (as defined by ICC 2022) fitting one or more of the following criteria:\n\n   * TP53 mutation (single- or multi-hit)\n   * Presence of inv(3) (q21.3q26.2) or t(3;3)(q21.3;q26.2)\n   * Adverse risk (as per ICC 2022) and \\>0.1% MRD by flow cytometry after 2 cycles of induction\n   * AML (any risk) with partial remission (\\\u003C10% blasts) after 2 cycles induction\n   * Early relapse (\\\u003C6 months) after chemotherapy alone (excluding t(16;16), inv(16) or t(8;21))\n4. Bone marrow performed within 28 days of starting conditioning chemotherapy demonstrates either:\n\n   * \\\u003C10% blasts\n   * \\>10% blasts with a hypocellular background (must be discussed with the trial team)\n5. Suitable fitness and organ function as per the following criteria:\n\n   * Glomerular filtration rate \\>50 mL\u002Fmin\u002F1.73m2\n   * Ejection fraction \\>50%\n   * FEV1 \\>65% without dyspnoea on mild activity\n   * AST\u002FALT \\\u003C3 x ULN\n   * Bilirubin \\\u003C1.5 x ULN (excluding Gilbert's syndrome)\n   * Performance Status (ECOG) of 0 or 1\n6. Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must agree to use appropriate, highly effective, contraception from the point of commencing therapy until 12 months after transplant\n\nEXCLUSION CRITERIA:\n\n1. AML Secondary to a myeloproliferative neoplasm\n2. Active CNS disease\n3. Prior allogeneic stem cell transplant\n4. Participation in another clinical trial that would alter any aspect of the transplant protocol or that aims to reduce the subsequent risk of relapse (discuss with trial team if unsure)\n5. History of cardiac arrhythmia\n6. Ischaemic heart disease, valvular heart disease or congestive cardiac failure\n7. Transient ischaemic attack or cerebrovascular accident\n8. Rheumatologic disease (SLE, RA, polymyositis, mixed CTD or polymyalgia rheumatica)\n9. Ulcerative colitis or Crohn's disease\n10. Liver cirrhosis\n11. Presence of an active second malignancy\n12. Uncontrolled infection, including viral reactivation (CMV, EBV)\n13. HIV positive\n14. Hepatitis B\u002FC active infection with measurable viral load (patients with chronic hepatitis B or C infection require clear documentation of absence of cirrhosis by either fibroscan or biopsy, regardless of viral load)\n15. Pregnancy, breastfeeding, unwilling to use contraception\n16. Contraindications to administration of pooled granulocytes\n17. Previous history of sensitivity to granulocytes\n18. Inability of patient to give informed consent\n19. Any other organ dysfunction or co-morbidity that precludes transplant in the opinion of the investigator\n20. Any concern by PI","55 Years",{"count":288,"type":22},50,[290,291],"PHASE1","PHASE2","Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death. Patients with certain mutations and those transplanted without first clearing their disease have very poor outcomes with most relapsing soon after transplant, and then surviving only a few months. A recent trial at the Royal Manchester Children's Hospital used cord blood stem cells alongside a type of white blood cell called 'granulocytes' and produced surprisingly good outcomes for children with very resistant leukaemia.\n\nGRACE is a clinical trial for adults (\\\u003C55 years) with Acute Myeloid Leukaemia that has not responded to chemotherapy or harbours mutations that predict a very poor response to conventional transplant. Participants will receive a transplant using umbilical cord blood and be given additional infusions of white blood cells, called granulocytes. The trial will be split into two parts:-The first will study the safety of this new approach. The experience of the investigators in children is that granulocyte infusions cause a fever, rash and expansion of another type of white blood cell called lymphocytes. Children that did not have this reaction did not respond to treatment. The investigators therefore believe that the reaction is necessary for the treatment to work, but the investigators must ensure that it is safe in adult patients. The trial design allows the investigators to determine the dose of granulocytes that is best tolerated and most likely to be effective.\n\nThe aim of the second part is to demonstrate that the new treatment is more effective than conventional transplantation.\n\nThe study will be conducted in three NHS transplant centres. Patients will be recruited over 36 months and followed up for a minimum of 1 year. The study is funded by Blood Cancer UK.",[294,295,296,297,298],"Acute Myeloid Leukemia","Stem Cell Transplantation","Stem Cell Transplantation, Hematopoietic","Cord Blood Stem Cell Transplantation","Cellular Therapy",[300,301,302,303,304,305,306],"Grace","granulocyte-augmented cord blood transplantation","poor risk acute myeloid leukaemia","Cord Blood Transplantation","Myelodysplastic Syndrome","TP53","MECOM","2026-03-10",{"date":309,"type":46},"2026-03-11",{"date":311,"type":22},"2026-02-09",{"date":313,"type":22},"2029-12-31",{"name":52,"class":53},3,{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":90,"sex":159,"minAge":160,"maxAge":260,"enrollmentInfo":323,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":54},"100516496","mothers-working-to-prevent-early-stillbirth-study-20-28-100516496","NCT06005272","Mothers Working to Prevent Early Stillbirth Study 20-28","MiNESS20-28","Cases\n\n* Bereaved mothers\u002Fparents who have recently birthed a singleton baby who died before\u002Fduring or immediately after labour between 20 and 28 weeks of pregnancy.\n* Baby has no evidence of congenital anomaly\n* Able to give written informed consent\n\nControls\n\n* Pregnant women\u002Fpeople with an ongoing pregnancy (at the target gestation) receiving antenatal care from a participating maternity unit, at a gestation matched to the distribution of stillbirths between 20 to 28 weeks of pregnancy in the same unit\n* Baby has no evidence of congenital anomaly\n* Able to give written informed consent",{"count":324,"type":22},948,"This project aims to identify factors linked to pregnancy losses occurring between 20 and 28 weeks of pregnancy that can be modified by changing mother's behaviour or healthcare provision.\n\nThe death of a child before birth (also called stillbirth or miscarriage) has enduring psychological, social and economic effects for women, their families and wider society. In 2015, the stillbirth rate in the UK was higher than comparable countries. The UK government has committed to reduce stillbirths by 50% by 2025. Presently, stillbirths after 28 weeks of pregnancy have reduced by 16% but there has been no change in losses between 20 and 28 weeks of pregnancy with 1,600 losses estimated to occur at this stage of pregnancy each year.\n\nIdentification of modifiable causes of stillbirth was identified as a research priority by the Stillbirth Priority Setting Partnership which involved over 1,000 participants, one third of whom were bereaved parents. The investigators previously completed a study of 291 women who had a late stillbirth (after 28 weeks of pregnancy) and 733 women who had a live baby in 41 maternity units in the UK. This study identified factors linked to stillbirth which can be changed including the position women go to sleep in, cigarette smoking and caffeine consumption. In addition, the investigators previously found changes in mother's perception of baby's movements, whether women had tests for diabetes or whether women were exposed to domestic violence or stressful situations. These factors can be addressed by different care in pregnancy. Information from this study has been included in national and international guidelines that aim to reduce stillbirth.\n\nThe investigators will use the same study type to identify factors associated with pregnancy loss between 20 and 28 weeks of pregnancy (early stillbirth). The investigators have asked parents who have experienced the death of a baby at these stages of pregnancy about the design of the study, the questions that would be asked and how best to approach bereaved parents. This led us to include miscarriages from 20-22 weeks of pregnancy that are not usually \"counted\" in UK stillbirth statistics. The investigators will need 316 women with stillbirth between 20 and 28 weeks of pregnancy and 632 women with an ongoing live pregnancy to participate in the study. All women will complete a questionnaire about themselves, their diet, behaviours and sleep, their baby's movements and pregnancy care. The investigators will compare information between women who have early stillbirth and those who have a live birth to identify factors associated with stillbirth at less than 28 weeks of pregnancy. The study findings will be disseminated in collaboration with patient organisations using effective ways to reach pregnant women. The investigators anticipate the findings from this study will be included in clinical practice guidelines and rapidly translated into antenatal care.",[327,223],"Stillbirth and Fetal Death","2026-02-24",{"date":330,"type":46},"2026-02-27",{"date":332,"type":46},"2023-09-01",{"date":334,"type":22},"2027-03-31",{"name":52,"class":53},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":136,"enrollmentInfo":343,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":54},"100624345","precision-pharmacogenetics-and-genotype-class-based-prediction-of-mavacamten-response-in-obstructive-hypertrophic-cardiomyopathy-100624345","NCT07408427","Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy","PRO-Gene Mava","Inclusion Criteria:\n\n* Participants above the age of 18 years, with a confirmed diagnosis of oHCM, not solely explained by abnormal loading conditions (e.g. significant hypertension, valvular disease).\n\nExclusion Criteria:\n\n* HCM phenocopies (e.g., amyloid, Fabry's disease)\n* Prior septal reduction therapy (within 6 months)\n* Contraindications to mavacamten (e.g., baseline LVEF \\\u003C 55%, pregnancy, uncontrolled heart failure)",{"count":344,"type":22},140,"This research study, aims to understand why a specific heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than for others. We believe the answer might be in our genes.\n\nThe study focuses on two key areas:\n\n1. The specific gene causing HCM:The study will investigate whether the type of gene causing the condition in a person influences how well mavacamten works for them.\n2. Each individual carry a certain gene that helps metabolise and process medication (otherwise known as pharmacogenetics). Our research will closely examine a gene called CYP2C19 to see if a person's natural processing speed (slow, normal, or fast) affects the medicine's performance. The study will also look for rare genetic variations that standard tests might miss.",[142],[144,348],"pharmacogenetics","2026-02-06",{"date":351,"type":46},"2026-02-13",{"date":353,"type":22},"2026-06",{"date":355,"type":22},"2029-12",{"name":52,"class":53},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":365,"targetDuration":139,"studyType":64,"phases":4,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":378,"leadSponsor":380,"locationsCount":381},"100552837","uk-cardiovascular-immune-mediated-inflammatory-diseases-cardio-imid-registry-study-100552837","NCT06478277","UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry Study","The UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry","CARDIO-IMID","Inclusion Criteria:\n\n1. Written informed consent\n2. Diagnosis of an IMID by a rheumatologist with categorisation into one of the following:\n\n   i. IMID-'higher risk' CVD: individuals who have a risk of developing CVD (based on traditional risk factors and\u002For IMID-specific factors) but no history of CVD\n   1. Coronary artery disease (CAD): specifically, a high pre-test probability of CAD based on clinical risk factors (e.g. QRISK3 score ≥10%) and\u002For elevated biochemical markers (high-sensitivity C-reactive protein ≥2mg\u002FL and\u002For Lipoprotein(a) ≥70mg\u002FdL)\n   2. Myopericardial involvement: Specific IMID and\u002For cardiovascular indicators that place at increased risk e.g. autoantibody associations, presence of peripheral myositis or other major organ involvement; incidental raised serum cardiac biomarkers (troponin and\u002For NT-pro BNP), on routine testing\n\n      ii. Incident (new) IMID-CVD: Patients with IMID that present with a new history of CVD\n\n   \u003C!-- -->\n\n   1. ASCVD i. Major adverse cardiovascular events (MACE):\n\n      \\- Non-fatal myocardial infarction.\n\n      \\- Non-fatal stroke of any classification, including reversible focal neurologic\n\n      \\- Defects with imaging evidence of a new cerebral lesion consistent with ischemia or haemorrhage.\n\n      ii. Other cardiovascular events not accounted for in the MACE-3 composite 2)a)i:\n\n      \\- Hospitalization for unstable angina\n\n      \\- Coronary revascularization\n\n      \\- Hospitalization for heart failure\n\n      \\- Transient Ischemic Attack (TIA)\n\n      \\- Peripheral Vascular Disease (PVD)\n      * Deep vein thrombosis (VTE) and\u002For pulmonary embolism \\[PE\\].\n   2. Myopericardial involvement: as diagnosed by a cardiology specialist with 'tier 2' cardiovascular imaging and\u002For other clinical and biochemical criteria in line with usual care\n\n      iii. Established IMID-CVD\n\n   a) Patients with IMID and a history of past cardiovascular event as detailed in 2) a) above.\n\n   b) Patients with a known history of myopericardial involvement as defined above in 2) b)\n\nBiological sub-study inclusion criteria\n\n* There are no additional inclusion criteria for this sub-study\n\nExtended protocol standard CMR sub-study inclusion criteria.\n\n* Participants that receive a CMR scan as standard of care\n\nExclusion Criteria:\n\n1. Age less than 18 years\n2. Unable to give informed consent\n\nBiological sub-study exclusion criteria:\n\n\\- There are no additional exclusion criteria for this sub-study\n\nCMR sub-study exclusion criteria:\n\nStandard of care contraindications to:\n\n1. CMR: metal implant eg metal fragments in the eye, pacemaker; claustrophobia; inability to lie flat\n2. Magnetic Resonance Imaging (MRI) contrast: renal failure with estimated glomerular filtration rate (eGFR) \\\u003C30,",{"count":366,"type":22},600,"The goal of this observational study is to develop a large, deeply characterised cohort that will be a platform for collaborative clinical and translational research into cardiovascular (CV) disease (CVD) and Immune-mediated-inflammatory-diseases (IMID). The main aim is to evaluate whether existing blood cardiac biomarkers predict adverse cardiovascular outcomes. The study will capture standard of care CV and associated health data (clinical, biochemistry\u002Fpathology and investigations) in patients across the IMIDs. Optional biological and\u002For imaging sub-studies will provide additional data and\u002For samples for associated analyses.",[369,370],"Cardiovascular Diseases","Immune-Mediated Inflammatory Diseases",[372,373,374],"Cardiovascular disease","Immune-mediated Inflammatory Diseases","Registry","2026-02-04",{"date":349,"type":46},{"date":375,"type":46},{"date":379,"type":22},"2028-08",{"name":52,"class":53},2,{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":136,"enrollmentInfo":389,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":4},"100618526","myocardial-energetic-restoration-in-the-treatment-of-obstructive-hypertrophic-cardiomyopathy-100618526","NCT07332767","Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy","MERIT HCM","Inclusion Criteria:\n\n* at least 18 years of age and\n* Have a confirmed diagnosis of oHCM that is not solely explained by abnormal loading conditions such as significant hypertension or valvular disease\n* Qualify for mavacamten therapy by exhibiting a peak Left Ventricular Outflow Tract (LVOT) gradient of ≥ 50mmHg at rest or with provocation, New York Heart Association (NYHA) functional class II or III symptoms, and a baseline Left Ventricular Ejection Fraction (LVEF) of ≥ 55%\n\nExclusion Criteria:\n\n* HCM phenocopies such as cardiac amyloidosis or Fabry's disease\n* Undergone a septal reduction therapy (myectomy or ablation) within the preceding 6 months\n* Any contraindications to mavacamten (e.g., baseline LVEF \\\u003C 55%, pregnancy\u002Fbreastfeeding)\n* Inability to safely undergo a cardiac MRI, such as having non-compatible metal implants or severe claustrophobia",{"count":390,"type":22},20,"Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart condition, where the heart muscles can thicken to the point of obstructing blood flow out of the heart. This condition is associated with a chronic state of energy loss in the heart muscle.\n\nTill more recently, a new class of medication (cardiac myosin inhibitors) have been introduced to directly target the heart muscle proteins (sarcomeres) to reduce the strength of contraction and relieve obstruction of blood flow out of the heart. While clinical trials have shown this class of medication significantly improves physical capacity and patient symptoms, it is still unclear, based on small scale published studies, where this improvement is achieved by restoring the fundamental energy balance within the heart.\n\nOur research study aims to answer this question and prove mechanistic insights of the use of this class of medication in the HCM population with blood flow obstruction (otherwise known as obstructive HCM) by using a specialised non-invasive MRI technique which accurately measures the heart energy score (specifically known as the PCr\u002FATP ratio) in each participant. Our objective is to determine how a patient with obstructive HCM have their energy scores affected, and improve over time with this medication therapy. If positive, this finding could establish the use of PCr\u002FATP ratio as a crucial, objective biomarker for monitoring therapeutic response and informing personalised dosing strategies for patient in the future.",[142],[144],"2025-12-29",{"date":396,"type":46},"2026-01-12",{"date":398,"type":22},"2026-04-30",{"date":400,"type":22},"2028-04",{"name":52,"class":53},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":54},"100612332","a-case-series-of-culturally-adapted-cbtp-for-black-people-in-the-uk-100612332","NCT07252206","A Case Series of Culturally-adapted CBTp for Black People in the UK","Culturally-adapted Cognitive-behavioural Therapy for Black Sub-Saharan African and Caribbean People Experiencing Psychosis: A Case Series","Inclusion Criteria:\n\n* Service users who identify as Black British, Black Caribbean, Black African, African-Caribbean or Mixed African\u002FCaribbean with at least one parent and\u002For grandparent born in a Sub-Saharan African or Caribbean country\n* People with a current ICD-10 schizophrenia spectrum disorder diagnosis, or who are currently receiving or have received support from an Early Intervention in Psychosis team\n* 16 years or older\n* Sufficient understanding of English to complete study measures and engage with CBTp\n\nExclusion Criteria:\n\n* Current, primary diagnosis of substance use disorder\n* Organic aetiology of psychosis\n* Lacking capacity to provide full informed consent\n* Currently experiencing a mental health crisis (i.e., are open to a home-based treatment team; are currently under Section of the Mental Health Act or have been under Section in the past 3 months) or immediate high risk to self or others (i.e., current suicidal intent or plans; unmanaged and intense non-suicidal self-injury)\n* Currently receiving CBTp or received CBTp within the preceding 3 months\n* Unwilling to participate in culturally-adapted CBTp",{"count":410,"type":22},6,[25],"The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis. The main question it aims to answer is:\n\nIs culturally-adapted CBT for psychosis feasible, acceptable to and safe for Black Sub-Saharan African and Caribbean people experiencing psychosis?\n\nParticipants will be asked to:\n\n* Answer some questionnaires about how things are at the moment\n* Attend up to 16 sessions of therapy\n* Answer the same questionnaires to see what has changed, if anything\n* Complete a semi-structured interview about their expectations and experience of therapy",[414,415],"Psychosis","Schizophrenia Spectrum Disorders","2025-11-25",{"date":418,"type":46},"2025-12-03",{"date":420,"type":22},"2026-01",{"date":422,"type":22},"2026-12",{"name":52,"class":53},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":90,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":54},"100611233","improving-the-accuracy-of-artificial-intelligence-triage-in-primary-care-100611233","NCT07237919","Improving the Accuracy of Artificial Intelligence Triage in Primary Care","Inclusion Criteria:\n\n* GP practices using the Patchs system\n\nExclusion Criteria:\n\n* N\u002FA",{"count":431,"type":22},226821,[25],"WHY ARE WE DOING THIS? When patients contact their GP practice, the first step is to work out what kind of help they need and how quickly it's needed. This is called 'triage' and is important for patient safety.\n\nArtificial Intelligence (AI) can help make triage faster. While AI is already being used in the NHS, we don't know how accurate it is or if it treats all patients fairly.\n\nWHAT WILL WE DO?\n\nWe will collect anonymised data from patients that use an AI triage system called Patchs in GP practices in England. The project will last four years. We will analyse the data in four steps:\n\n1. Look at data from GP practices using Patchs without AI triage to see how they currently triage patients and what problems they face.\n2. Use data from GP practices using Patchs (both with AI on and off) to make the AI triage more accurate.\n3. Check data from GP practices using Patchs with AI triage off to measure how well the updated AI system works.\n4. Give the improved AI triage system to GP practices already using AI.\n\nAt each step, we will check whether patients from different backgrounds are treated fairly.\n\nHOW WILL WE ANALYSE THE DATA? We will use statistical methods to compare the triage decisions made by the AI with those made by clinical staff. This analysis will also be used to check that the AI works fairly for patients from different backgrounds.\n\nWHAT DIFFERENCE WILL WE MAKE? Our research will show the problems with triage and explain how an improved AI system could help patients get the care they need more quickly.",[435,436],"Primary Care","Artificial Intelligence (AI)","2025-11-14",{"date":439,"type":46},"2025-11-20",{"date":441,"type":46},"2025-04-01",{"date":443,"type":22},"2029-07",{"name":52,"class":53},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":465},"100582826","apace---feasibility-of-using-accelerometers-to-measure-physical-activity-in-cancer-patients-on-early-phase-clinical-trials-100582826","NCT06868355","APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials","APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials. A Feasibility Study Evaluating the Use of Accelerometers to Capture Physical Activity Levels in Cancer Patients on Early Phase Clinical Trials","APACE","Inclusion Criteria:\n\n* Voluntary informed consent.\n* Aged at least 16 years.\n* Consented to an early phase clinical trial.\n* Willingness to wear a device for the duration of the study.\n* Willingness to comply with scheduled study procedures.\n* ECOG PS 0 or 1.\n\nExclusion Criteria:\n\n* Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements.\n* Patient deemed ineligible for enrolment onto an early phase clinical trial.",{"count":454,"type":22},40,"Increased physical activity has been shown to improve outcomes for cancer patients, however the measure of activity is highly variable and understudied in cancer patients on early phase clinical trials where activity is used as a criteria for eligibility. Additionally, more than half of cancer patients experience fatigue at some point in their treatment with exercise and psychosocial interventions currently recommended as interventions. Therefore, it is important to be able to more accurately measure activity and fatigue in cancer patients to ensure adequate intervention, management and appropriate access to treatment.\n\nThis proposal is a non-interventional feasibility study designed to collect activity and sleep data from patients with advanced cancer newly enrolled in early phase clinical trials. The data will be collected over a 5-6 week period using a wearable accelerometer device. This study will be conducted concurrently with the early phase trial related activities\u002Ftreatment and will have no impact on a patient's clinical pathway. Data generated from the study will be used to evaluate the feasibility of collecting activity and sleep data from patients with advanced cancer on early phase clinical trials.\n\nIn this study, participants in the UK will be able to opt-in to using eNutri, a web-based graphical food frequency questionnaire (FFQ), and provide feedback on its usability. The output of eNUTRI will help us understand if there is a use for eNutri in cancer care environments for a range of purposes such as providing nutritional support for cancer patients, and exploring drug-nutrient interactions on the patient outcome.",[95],"2025-08-08",{"date":459,"type":46},"2025-08-14",{"date":461,"type":46},"2023-09-28",{"date":463,"type":22},"2025-09-30",{"name":52,"class":53},8,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":54},"100445135","investigating-the-tumour-immune-response-of-radiotherapy-100445135","NCT05076500","Investigating the Tumour Immune Response of Radiotherapy","TIMM-RAD","Inclusion Criteria:\n\n* Histologically confirmed cancer, Stage I-IV, in one of the following: Cervical, rectal, nodal Non-Hodgkin lymphoma, cutaneous lymphoma, Head \\& neck cancer\n* Diagnostic\u002Fpre-treatment biopsy confirmed suitable for translational research \\*\n* Performance status - ECOG 0-2 (Refer to appendix 1), ECOG 3 allowed for arm F (unrelated to underlying cancer) as this group of patients often have ECOG 3 due to age and comorbidities.\n* Age ≥ 18; no upper age limit.\n* Participant considered suitable for radiotherapy\n* Before participant registration, written informed consent must be given according to GCP and national regulations.\n\n  \\*Pre-treatment biopsy must be from the gross tumour volume within the planned radiation field and must also:\n* Have been formalin fixed for \\>12h and \\\u003C72h\n* Have tumour tissue and morphology confirmed by H\\&E staining\n* Contain sufficient tumour cells (approximately 100)\n\nExclusion Criteria:\n\n* Participants deemed unsuitable for a biopsy (during or following radiotherapy) in the opinion of the treating oncologist.\n* Participants who have received chemotherapy within 28 days of starting radiotherapy.\n* Participants with intercurrent or past history of hepatitis B, C or human immunodeficiency virus infection if known. A negative test result for hepatitis B, C and HIV infection is required prior to inclusion in the study.",{"count":163,"type":22},"This study aims to investigate immune changes which occur before and following standard radiotherapy in a range of tumour types. We will collect tissue and blood samples before and after radiation treatment from participants across six cancer types: cervical, rectal, Head and Neck cancer, nodal non-Hodgkin lymphoma, cutaneous lymphoma and cutaneous squamous cell carcinoma\u002F basal cell carcinoma.",[95],"2025-06-05",{"date":478,"type":46},"2025-06-11",{"date":480,"type":46},"2021-07-14",{"date":482,"type":22},"2026-08-14",{"name":52,"class":53},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":494,"conditions":495,"keywords":501,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":54},"100591187","investigating-the-impact-of-sepsis-phenotypes-on-antibiotic-treatment-in-patients-with-severe-pneumonia-and-sepsis-100591187","NCT06977165","Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis","Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis: a Prospective Observational Cohort Study","SIPRES","Inclusion Criteria:\n\n* age ≥ 18 years;\n* admitted to intensive care and receiving at least one-organ supportive care;\n* treated for presumed or confirmed lower respiratory infection;\n* receiving or about to receive piperacillin\u002Ftazobactam as part of standard clinical care;\n* valid informed consent or enrolment through deferred consent pathway appropriate.\n\nExclusion Criteria:\n\n* unlikely to survive 24 hours as judged by the treating physician;\n* study antimicrobial started more than 24 hours prior.",{"count":493,"type":22},119,"Aim of the research: To find out why antibiotics work differently in certain patients with severe pneumonia and sepsis.\n\nBackground: Individuals can become very unwell from pneumonia, sometimes requiring admission to hospital or even the intensive care unit (ICU). In some cases, pneumonia can lead to a condition called sepsis, which can be deadly if not treated quickly. In the UK, approximately 30,000 patients die from pneumonia every year. Clinicians use antibiotic injections to treat life-threatening infections such as severe pneumonia. After being injected into the bloodstream, antibiotics quickly spread throughout the body, attacking the infection. Antibiotics are eventually broken down and removed from the body by the kidneys and other organs. However, antibiotics fail to achieve the same consistent result for every patient. This may be to do with the way the antibiotics travel through and are removed from the body, leading to different antibiotic levels in the blood at any one time. Low antibiotic levels can result in worse outcomes and antibiotic resistance. Patients can be grouped based on how their immune system reacts to infections. The SIPRES Study aims to explore if these previously described groups explain the difference in antibiotic levels in patients with severe pneumonia and sepsis.\n\nProcedures: We will study how adult patients with severe pneumonia respond when treated with the most commonly used antibiotic in the ICU called piperacillin\u002Ftazobactam. Alongside information on how quickly patients get better and how long they need to stay in hospital or in ICU, we will collect blood samples to measure antibiotic levels and assess each patient's immune system at two time points during their treatment. This will allow us to measure antibiotic levels in blood at different times and group patients based on their immune system reaction to infection. We will describe the range of antibiotic levels seen in the different immune system reaction groups using mathematical and statistical models.\n\nPatient involvement: We are working closely with people who have experienced severe pneumonia and will work with two patient partners and a patient advisory group to help shape this research. Patient contributors have already shaped the development of the funding application and identified important study outcomes. Patients we have spoken to are concerned over the appropriate dosing of antibiotics and appreciate the need for improved and precise approaches to treating severe infections. Moving forward, patient partners will help finalise the protocol, develop patient and public facing materials, provide their perspective on the study results and shape plans to share the outcomes of the study more broadly.\n\nPotential impact: The SIPRES Study will help identify a group of patients at risk of low antibiotic levels in blood, who are less likely to improve with treatment and more likely to develop antibiotic resistance. Mathematical models that can help clinicians personalise antibiotic dosing for each critically ill patient with severe pneumonia will be developed. Findings have the potential to limit the development of antibiotic resistance and help patients survive and get better faster so that they can return to their normal daily lives. Individualised dosing for patients with low antibiotic levels, as opposed to 'one size fits all' prescribing, also has the potential to more efficiently allocate scarce resources to those who will benefit the most.",[496,497,498,499,500],"Respiration Disorders","Respiratory Failure","Sepsis","Infection in ICU","Pneumonia",[502,503,504,505,506],"sepsis","pneumonia","therapeutic drug monitoring","beta-lactam antibiotics","piperacillin-tazobactam","2025-05-08",{"date":509,"type":46},"2025-05-18",{"date":511,"type":22},"2025-09-01",{"date":276,"type":22},{"name":52,"class":53},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":90,"sex":159,"minAge":160,"maxAge":260,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":528,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":54},"100589312","validation-of-sensors-for-long-term-non-invasive-fetal-monitoring-100589312","NCT06952777","Validation of Sensors for Long-term Non-Invasive Fetal Monitoring","Measurement and Validation of Fetal Heart and Fetal Movement Signals Detected Via Non-adhesive Sensors","Inclusion Criteria:\n\n* Participants will be included if they have a non-anomalous singleton pregnancy after 28 weeks' gestation with an estimated fetal weight \\>10th centile \\\u003C 90th centile. Participants will be 16 years or over in order that they can give independent consent.\n\nExclusion Criteria:\n\n* Participants will be excluded if there are fetal anomalies (as defined by the NHS Fetal Anomaly Screening Programme - https:\u002F\u002Fwww.gov.uk\u002Fguidance\u002Ffetal-anomaly-screening-programme-overview), it is a multiple pregnancy, there is evidence of Fetal Growth Restriction (Estimated Fetal Weight \\\u003C10th centile) or if participants cannot speak or do not understand fluent English. Participants will not be able to participate if they are unable to give informed consent. Participants \\\u003C16 years of age will be excluded from this study.",{"count":522,"type":22},69,[25],"A multidisciplinary team of a doctor and engineers have developed a new sensor that will be able to detect mothers' and babies' heartbeat and babies movements in late pregnancy. This sensor can be placed in contact with the mothers' skin over the pregnant uterus without having to be stuck down. We anticipate that this sensor would allow us to monitor babies for longer periods of time which might help us to better identify babies who are being deprived of oxygen during pregnancy. We need to test these sensors on women in late pregnancy for two reasons. Firstly, we need to ensure they reliably measure mother and babies heart rates without interference from movement or other electrical equipment. Secondly we need to ensure that the information they provide is accurate (compared to current measurement techniques).\n\nWe will carry out two related studies. The first will include up to 24 women to develop the sensors to ensure that they can obtain consistent signals from mothers' and babies' heartbeats without interference from movement and other electronic devices. We will adjust the electronics in the sensors to ensure they give the best signal. The second will include up to 45 women to see whether the information detected by the sensors is comparable to existing technologies. This information will help us to see whether these sensors can be organised into a new device for fetal monitoring which can then be tested.",[526,527],"Fetal Distress With Antenatal Problem","Fetal Growth Retardation",[529,530],"Fetal monitoring","Fetal heart rate monitoring","2025-04-23",{"date":533,"type":46},"2025-05-01",{"date":535,"type":46},"2024-06-01",{"date":537,"type":22},"2025-12-31",{"name":52,"class":53},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":315},"100482842","precision-medicine-for-stem-cell-transplantation-100482842","NCT05567289","Precision Medicine for Stem Cell Transplantation","PM-SCT","Inclusion Criteria:\n\n* Any recipient of allogeneic haematopoietic stem cell transplantation (HSCT)\n* Children\u002Finfants may participate, there is no age restriction\n* Patients participating in other clinical trials remain eligible\n\nExclusion Criteria:\n\n* Weight \\\u003C5kg\n* Recipients of autologous stem cell transplants",{"count":547,"type":22},300,"A study of patients undergoing haematopoietic stem cell transplantation, a procedure in which patients are infused with stem cells from a donor, resulting in a new immune system that eliminates cancer or replaces diseased bone marrow. This study aims to develop new blood tests that predict the onset of acute graft-versus-host disease (aGvHD) and leukaemia relapse, two life-threatening complications that frequently limit the success of treatment. Predictive tests would allow doctors to individualise prophylaxis and intervene early to abort complications before they develop. The study will also create a large collection of clinically annotated blood samples from 300 transplant recipients to support future research and provide a resource to the transplant research community.",[550],"Haematopoietic Stem Cell Transplantation","2025-03-31",{"date":553,"type":46},"2025-04-03",{"date":555,"type":46},"2023-06-06",{"date":379,"type":22},{"name":52,"class":53},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":568,"conditions":569,"keywords":573,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":583,"locationsCount":54},"100582037","outcomes-of-a-pre-operative-exercise-programme-for-live-donor-and-recipient-kidney-transplant-patients-100582037","NCT06858098","Outcomes of a Pre-operative Exercise Programme for Live Donor and Recipient Kidney Transplant Patients","Outcomes of a Pre-operative Exercise Regimen for Patients Undergoing Hand-assisted Liver Donor Nephrectomy and Transplantation","OPERATe","Inclusion Criteria:\n\n* Aged 18 years and over\n* Live kidney donor or transplant recipient\n\nExclusion Criteria:\n\n* Deceased donor transplant recipient\n* Patient unable to wear or tolerate wearable device\n* Unstable angina, recent myocardial infarction, recent cerebrovascular accident or new arrythmia\n* Patient declines or is unable to participate in the exercise programme\n* Lacks capacity to give informed consent to participate in trial\n* Non-English speaking\n* No access to a smart device to download application",{"count":454,"type":22},[25],"The goal of this clinical trial is to learn if a pre-operative outpatient exercise programme, monitored by a smart wearable device is acceptable to live kidney donor and recipient transplant patients. It will also look at the impact of prehabilitation on post operative outcomes. The main questions it aims to answer are:\n\nIs it feasible for renal transplant patients and live kidney donors to participate in a prehabilitation programme in combination with a piece of wearable technology?\n\nAre transplant outcomes improved by prehabilitation regimens delivered by video instruction?\n\nAre there discernible perioperative digital signatures provided by the wearable that link to surgical outcomes?\n\nIs the quality of perioperative sleep linked to surgical outcomes?\n\nParticipants will:\n\nWear a wrist or ring worn wearable device for a total of 14 weeks (2 week baseline, 6 week pre op and 6 week post op) Engage in a 6 week pre operative exercise programme at home\u002Fgym Keep a diary and answer surveys on their experience of the exercise regimen and wearable device",[570,571,572],"Kidney Transplant","Kidney Transplant Donor","Kidney Transplant Recipient",[574,575,576],"live kidney transplant","prehabilitation","wearable devices","2025-03-24",{"date":579,"type":46},"2025-03-25",{"date":533,"type":22},{"date":582,"type":22},"2026-09-01",{"name":52,"class":53},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":591,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":23,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":54},"100583919","a-compassionate-focused-intervention-for-older-people-with-bipolar-disorder-100583919","NCT06882590","A Compassionate-focused Intervention for Older People with Bipolar Disorder","A Brief Compassionate-focused Intervention for Older People with Bipolar Disorder","Inclusion Criteria:\n\n* Adults aged 60 years and above.\n* Have a nominated healthcare professional (i.e. GP\u002FCare Coordinator)\n* Meet the criteria for a diagnosis of bipolar disorder I or II according to the MINI.\n* Score of \\>57 on Ruminative Response Scale (RRS)\n* Be able to provide written informed consent.\n* Be able to speak sufficient English to engage in the assessments and intervention.\n\nExclusion Criteria:\n\n* Currently in an episode of mania or hypomania according to the MINI.\n* Experiencing 'severe depression' according to the Hamilton Depression Rating Scale, which equates to a score of over 24.\n* MoCA score of \\\u003C22 to exclude for moderate and severe cognitive impairment.\n* Currently receiving psychological therapy.","60 Years","90 Years",{"count":410,"type":22},[25],"The aim of this study is to determine whether it is feasible to deliver a 9-session compassionate-focused therapy for older people with bipolar disorder. Participants will be asked to complete baseline measures and at post-intervention follow-up (12 weeks and 24 weeks) to understand any potential clinical benefits of the therapy.",[597],"Bipolar Disorder I or II",[599,600,601,602,603,604],"Compassion-Focused Therapy","Older Adults","Rumination","Bipolar Disorder","Guilt","Shame","2025-03-16",{"date":607,"type":46},"2025-03-18",{"date":609,"type":22},"2025-07-01",{"date":611,"type":22},"2026-04",{"name":52,"class":53},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":90,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":54},"100584065","aftereffects-of-pes-preconditioned-with-rtms-on-the-human-pharyngeal-motor-cortex-100584065","NCT06884488","Aftereffects of PES Preconditioned with RTMS on the Human Pharyngeal Motor Cortex","Effect of Preconditioning of Human Pharyngeal Motor Cortex by Low Frequency Repetitive Transcranial Magnetic Stimulation on Enhancing Cortical Excitability Induced by Pharyngeal Electrical Stimulation","Inclusion Criteria:\n\nHealthy volunteers over the age of 18 will be recruited through adverts placed around Salford Royal Hospital, on a University of Manchester website which advertises for research volunteers and through a departmental database of volunteers who have expressed an interest in future research. There is no upper age limit for potential participants.\n\nExclusion Criteria:\n\nThe presence or a history of:\n\n1. Epilepsy\n2. Cardiac pacemaker\n3. Previous brain surgery\n4. Previous swallowing problems\n5. The use of medication which acts on the central nervous system\n6. Any implanted metal in the head\n7. Pregnancy (self-declared)",{"count":621,"type":22},14,[25],"The goal of this interventional study is to optimize the excitatory brain effects of combined neuromodulatory therapies on swallowing areas of the brain. The main question it aims to answer is:\n\nDoes preconditioning with 1 Hertz (Hz) repetitive transcranial magnetic stimulation (rTMS) delivered over hemispheric pharyngeal areas enhance the activating effects of pharyngeal electrical stimulation (PES) on cortical excitability?\n\nParticipants will:\n\n* Visit the department three times, with at least a one-week gap between visits.\n* Undergo baseline measurements for Pharyngeal motor evoked potential (PMEP) and Thenar motor evoked potential (TMEP), involving an electromyography (EMG) pharyngeal catheter inserted into the pharynx and gel electrodes to detect muscle activity.\n* Be randomly allocated to one of the three preconditioning-conditioning procedures during each visit : 1Hz rTMS followed by 5Hz PES, sham 1Hz rTMS followed by 5Hz PES, and 1Hz rTMS followed by sham 5Hz PES\n\n  1. Real rTMS will involve a figure-of-eight coil flat against the head delivering 1Hz stimulation at 90% of the thenar resting motor threshold.\n  2. Sham rTMS will involve holding the coil perpendicular to the scalp to prevent brain stimulation.\n  3. PES will involve a catheter delivering 0.2-ms pulses at 5Hz and 75% of the maximal tolerated intensity for 10 minutes. Sham PES will involve deactivating the current generator.\n* Complete PMEP and TMEP measurements at baseline before intervention and every 15 minutes from 0 - 60 minutes after the rTMS-PES procedure.\n* Complete a survey regarding tolerability and safety at the end of each visit.",[625],"Healthy Subjects (HS)","2025-03-13",{"date":628,"type":46},"2025-03-19",{"date":630,"type":46},"2024-09-14",{"date":632,"type":22},"2025-08-31",{"name":52,"class":53},""]